ClinicalTrials.gg
RecruitingNCT06099158DANLOGIC-HFUpdated Oct 29, 2026

Danish Pragmatic Randomized Trial to Evaluate the Effect of HeartLogic-Guided Management on Heart Failure Outcomes

An interventional study of HeartLogic in Heart Failure, sponsored by Tor Biering-Sørensen. Recruiting at 5 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Tor Biering-Sørensen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.
Updated Oct 29, 2026Study contact changed4 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,428
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 242 studies in Heart Failure with a site in Denmark — 52 open to participants now, 60 under way, 9 of them phase 3. Heart Failure · Denmark.

Planned enrollment
42nd of 187
1,428 · median 197
Started
2024
with 16 others
No phase
89 of 242
20 open now
Primary completion
2027-12
later than 28 of 59 live
Registered
203rd of 242
by date

Among the 242 studies in Heart Failure with a site in Denmark, this one is the 42nd largest by planned enrollment of the 187 interventional ones that give a count, is one of 17 that started in 2024, is one of 89 with no phase, reaches primary completion later than 28 of the 59 other live ones, and was the 203rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

52 of the 242 studies in Heart Failure with a site in Denmark are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 242 studies in Heart Failure with a site in Denmark, or all of them as a file.
02

Study summary

The purpose of the study is to assess the impact of HeartLogic-guided management on clinical outcomes among patients implanted with an eligible cardiac device.

Read the detailed description

The study is a pragmatic, registry-based, randomized controlled trial. Eligible patients in Denmark will be randomized 1:1 to either HeartLogic-guided management or usual care. During the trial, patients in the HeartLogic arm will be contacted by the study team in case of any HeartLogic alerts for evaluation and treatment decisions. There will be no mandatory in-person visits scheduled in the trial. HeartLogic alerts will be managed according to a prespecified management guide. Trial data besides device-related data will be retrieved from the Danish nationwide health registries including baseline information and endpoint data. The control group will receive usual HF care in the Danish health system without the involvement of the study team. The study will comply with the standards of the CONSORT statement and the principles of the Declaration of Helsinki.

03

Conditions studied

  • Heart Failure

Keywords

  • Pragmatic
  • Heart disease
  • ICD
  • CRT-D
  • Pacemaker
  • Registry
  • HeartLogic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Implanted with a CRT-D or ICD device that has HeartLogic capability and ability to change HeartLogic enablement per randomization
  2. Age ≥18 years
  3. Compliant with remote monitoring and not listed in the LATITUDE™ remote monitoring system as "not monitored"

Exclusion criteria

Exclusion Criteria:

There are no specific exclusion criteria for the trial.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,428 participants (estimated)

Study arms

  • Experimental
    HeartLogic-guided management

    HeartLogic alerts will be transmitted to the study team, which will subsequently contact the participant to assess any treatment needs. Treatment needs will be assessed according to current clinical practice guidelines.

    Other: HeartLogic

  • No intervention
    Standard care

    The control group will receive usual HF care in the Danish health system.

Interventions

  • OtherHeartLogic

    HeartLogic alerts will be managed according to a standardized alert management guide to ensure uniform reactions to HeartLogic alerts.

06

What researchers measure

Primary outcomes

  1. Composite endpoint of hospitalization for heart failure or all-cause death (first event)

    Time frame: 42 months

Secondary outcomes

  1. Composite endpoint of hospitalization for heart failure or all-cause death (recurrent events)

    Time frame: 42 months

  2. Hospitalization for heart failure (first event)

    Time frame: 42 months

  3. All-cause hospitalization

    Time frame: 42 months

  4. All-cause mortality

    Time frame: 42 months

Other outcomes

  1. Hospitalizations for heart failure (recurrent events)

    Time frame: 42 months

  2. Hierarchical composite of all-cause mortality, total number of heart failure hospitalizations, and total number of all-cause hospitalizations

    Time frame: 42 months

  3. All-cause readmission within 30 days after hospitalization for heart failure

    Time frame: 42 months

  4. Hospitalization for any cardiovascular disease

    Time frame: 42 months

  5. Hospitalization for any cardio-respiratory disease

    Time frame: 42 months

  6. Hospitalization for atrial fibrillation

    Time frame: 42 months

  7. Atrial fibrillation burden

    Time frame: 42 months

  8. Hospitalization for cardiac arrest

    Time frame: 42 months

  9. Ventricular tachyarrhythmia leading to anti-tachycardia pacing and/or shock

    Time frame: 42 months

  10. Cardiovascular mortality

    Time frame: 42 months

  11. Incident heart failure (among participants without heart failure at baseline)

    Time frame: 42 months

  12. Days alive and out of hospital

    Time frame: 42 months

  13. Length of hospital stay

    Time frame: 42 months

  14. Use of guideline-directed medical therapy for heart failure

    Time frame: 42 months

  15. HeartLogic alert rate

    Time frame: 42 months

  16. Average HeartLogic index

    Time frame: 42 months

  17. Median HeartLogic alert length

    Time frame: 42 months

  18. % time in HeartLogic alert

    Time frame: 42 months

  19. Maximal observed HeartLogic index

    Time frame: 42 months

  20. Time from HeartLogic alert to clinical event

    Time frame: 42 months

  21. Individual HeartLogic sensor trends

    Time frame: 42 months

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be collected from Danish administrative health registries, which are subject to Danish legislation and can only be made available to a third party under certain conditions. Please contact the sponsor-investigator in case of any inquiries.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2027, 42 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 42 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Oct 25, 2023
StartActual
May 31, 2024
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added
Show 4 added (4 Denmark)
  • Aarhus University Hospital · Aarhus, Denmark
  • Rigshospitalet · Copenhagen, Denmark
  • Odense University Hospital · Odense, Denmark
  • Zealand University Hospital · Roskilde, Denmark
Oct 29, 2026
Contact
Study contact changed: n•••@regionh.dk · •••4794→f•••@regionh.dk · •••7157; m•••@regionh.dk · •••7345→l•••@regionh.dk · •••9531. See the current contact
Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte · Hellerup, DenmarkContact n•••@regionh.dk · •••4794→f•••@regionh.dk · •••7157Contact m•••@regionh.dk · •••7345→l•••@regionh.dk · •••9531
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    4 sites added
    Show 4 added (4 Denmark)
    • Aarhus University Hospital · Aarhus, Denmark
    • Rigshospitalet · Copenhagen, Denmark
    • Odense University Hospital · Odense, Denmark
    • Zealand University Hospital · Roskilde, Denmark
    Contact Study contact changed: n•••@regionh.dk · •••4794→f•••@regionh.dk · •••7157; m•••@regionh.dk · •••7345→l•••@regionh.dk · •••9531. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte · Hellerup, DenmarkContact n•••@regionh.dk · •••4794→f•••@regionh.dk · •••7157Contact m•••@regionh.dk · •••7345→l•••@regionh.dk · •••9531
    + 3 other changes: verification date, oversight details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06099158
Lead sponsor
Tor Biering-Sørensen
Responsible party
Tor Biering-Sørensen (Professor, MD, MSc, MPH, PhD, MP, Herlev and Gentofte Hospital) — Sponsor-investigator
First posted
Oct 25, 2023
Start date
May 31, 2024
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Frederik Holme Fussing, MD
Contact
frederik.holme.fussing@regionh.dk
+4521547157
Lise Witten Davodian, MD
Contact
lise.witten.davodian@regionh.dk
+4521639531
Tor Biering-Sørensen, MD, MSc, MPH, PhD
study chair · Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion